Search Results

A Multicenter, randomized, open label, Phase 3 Trial of Trastuzumab Deruxtecan (ENHERTU®) plus chemotherapy plus or minus Pembrolizumab versus chemotherapy plus Trastuzumab plus or minus Pembrolizumab as first line treatment in participants with unresectable, locally advanced or metastatic HER2-postive Gastric or GEJ cancer. (Destiny- Gastric05) (Trial of Trastuzumab Deruxtecan (ENHERTU®) plus chemotherapy plus or minus…

NX-5948-201: A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton’s Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i) MOA: NX-5948 (bexobrutideg) is a CTM that induces the degradation of BTK in cells through…

A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer MOA: ZL-1310 is an ADC that targets DLL3 and contains a topoisomerase I inhibitor payload Key Eligibility Criteria: Confirmed diagnosis of SCLC Archival tumor tissue or fresh tumor tissue…

Reid Sullivan has been working as a physician assistant with a focus in oncology since 2025. She received her bachelor’s degree in Neurobiology and Physiology at the University of Maryland College Park. Reid then went on to earn her master’s degree in Physician Assistant Studies at the University of Pittsburgh. She is board certified by…